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Abstract
Overweight and obesity are strongly associated with endometrial cancer. Several independent genome-wide association studies
recently identified two common polymorphisms, FTO rs9939609 and MC4R rs17782313, that are linked to increased body weight
and obesity. We examined the association of FTO rs9939609 and MC4R rs17782313 with endometrial cancer risk in a pooled analysis
of nine case-control studies within the Epidemiology of Endometrial Cancer Consortium (E2C2). This analysis included 3601 non-
Hispanic white women with histologically-confirmed endometrial carcinoma and 5275 frequency-matched controls. Unconditional
logistic regression models were used to assess the relation of FTO rs9939609 and MC4R rs17782313 genotypes to the risk of
endometrial cancer. Among control women, both the FTO rs9939609 A and MC4R rs17782313 C alleles were associated with a 16%
increased risk of being overweight (p=0.001 and p=0.004, respectively). In case-control analyses, carriers of the FTO rs9939609 AA
genotype were at increased risk of endometrial carcinoma compared to women with the TT genotype [odds ratio (OR) =1.17; 95%
confidence interval (CI): 1.03–1.32, p=0.01]. However, this association was no longer apparent after adjusting for body mass index
(BMI), suggesting mediation of the gene-disease effect through body weight. The MC4R rs17782313 polymorphism was not related
to endometrial cancer risk (per allele OR=0.98; 95% CI: 0.91–1.06; p=0.68). FTO rs9939609 is a susceptibility marker for white non-
Hispanic women at higher risk of endometrial cancer. Although FTO rs9939609 alone might have limited clinical or public health
significance for identifying women at high risk for endometrial cancer beyond that of excess body weight, further investigation of
obesity-related genetic markers might help to identify the pathways that influence endometrial carcinogenesis.
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Introduction
Endometrial cancer is the most common invasive gynecologic
cancer in U.S. women with an estimated 43,470 new cases
expected in 2010 [1]. Obesity is a well established risk factor for
endometrial cancer among both premenopausal and postmeno-
pausal women [2]. Adult obesity is associated with a 2- to 5-fold
increased risk for endometrial cancer and may account for 40% of
endometrial cancer incidence [2,3]. Etiologic models of endome-
trial carcinogenesis have focused primarily on the role of steroid
hormones, especially the effect of a deficiency in progestagen
relative to estrogen on endometrial cells [4,5]. According to the
‘unopposed estrogen’ hypothesis, the mitogenic effects of estrogen
on the endometrium, especially if not counterbalanced by
progestagen, increase the risk of malignancy. Adipocytes are the
primary source of estrogen in postmenopausal women when the
ovarian production of estrogen has ceased [6]. Obesity in
postmenopausal women enhances circulating levels of estrogen
through increased production and aromatization of androstenedi-
one in adipose tissue, as well as decreased production of sex-
hormone-binding globulin and reduced 2-hydroxylation of
estradiol [7]. Among premenopausal women, obesity is thought
to contribute to endometrial cancer risk through an association
with progesterone deficiency during the luteal phase of the
menstrual cycle, resulting in cellular proliferation and reduced
desquamation of the endometrium [5,7].
Recently, several independent large-scale genome-wide associ-
ation studies (GWAS) reported an association of fat mass and obesity
associated (FTO; MIM: 610966) and melanocortin-4 receptor (MC4R;
MIM: 155541) gene polymorphisms with obesity and BMI in
Caucasian populations [8–12]. Associations of BMI with common
variants in these two loci have been reproduced in multiple studies
[13,14]. Carriage of the FTO rs9939609 A and MC4R rs17782313
C alleles was estimated to increase the risk of obesity by 31% [8]
and 12% [11], respectively.
The protein encoded by FTO has been described as a Fe(II)-
and 2-oxoglutarate-dependent oxygenase that might operate as a
DNA demethylase. The human FTO gene is expressed in many
tissues including mesenteric fat, pancreas, liver and adipose tissue,
with the highest concentrations found in the hypothalamus [8,15].
Experimental animal studies provide direct functional evidence
that FTO underlies obesity [16]. Two studies have demonstrated
that FTO gene expression in the arcuate nucleus of the
hypothalamus is regulated by fasting [17,18], suggesting that
FTO may be important to the control of energy homeostasis. The
MC4R gene encodes the MC4 protein, a ubiquitously expressed G-
protein-coupled receptor that binds a-melanocyte stimulating
hormone (a-MSH) [19]. Experimental studies show that MC4R is
a key regulator of energy balance, influencing food intake and
energy expenditure through functionally divergent central mela-
nocortin neuronal pathways [20].
To examine the relation between the obesity-associated FTO
rs9939609 and MC4R rs17782313 and endometrial cancer risk,
we utilized pooled data within the Epidemiology of Endometrial
Cancer Consortium (E2C2) [21]. We also evaluated the
association of these single nucleotide polymorphisms (SNPs)
with the endometrioid histological type of endometrial carcino-
ma. Endometrioid carcinoma comprises approximately 80% of
all sporadic endometrial cancers [22]. It is a prototypical
estrogen-dependent tumor with a strong, definitive link to
obesity. Thus, we hypothesized a stronger association of the
FTO rs9939609 A allele and MC4R rs17782313 C allele and risk
of the endometrioid type of endometrial carcinoma than with
nonendometrioid types.
Results
The FTO rs9939609 minor allele (A) frequency among pooled
controls was 0.40 (range by study: 0.39 to 0.47) (Table S1). The
MC4R rs17782313 minor allele (C) frequency among controls was
0.25 (range: 0.23 to 0.28).
The minor alleles for both FTO rs9939609 and MC4R
rs17782313 were associated with a 16% per allele increased risk
of being overweight (p=0.001 and p=0.004, respectively)
(Table 1).
In the pooled analysis, the FTO rs9939609 AA genotype was
associated with an increased risk of endometrial cancer
(OR=1.17; 95% CI: 1.03–1.32; p=0.01) compared to women
with the TT genotype (Table 2). No heterogeneity of the genotype
associations with endometrial cancer was observed by study in any
of the models (Table S2 and Figure 1). Excluding WISE study
(with genotypes deviating from HWE) did not alter the association
of SNPs with endometrial cancer risk (OR=1.15; 95% CI: 1.01–
1.32; p=0.04). The FTO rs9939609 association with risk remained
consistent in the analysis restricted to incident cases in which the
TORONTO study participants were excluded (OR=1.18; 95%
CI: 1.03–1.35; p=0.02). No heterogeneity of effects was observed
between the TORONTO study and studies including incident
cases only (p=0.78). In the subset of women with BMI data
available, the association of the FTO rs9939609 AA genotype with
risk remained the same (Table 3). However, the association of the
FTO rs9939609 A allele with risk was no longer observed after
adjusting for BMI (Table 3) or in the analysis by BMI strata
(Table S3). The majority of cases were diagnosed with
endometrioid carcinomas (N=1,419 cases; 63%). In the analyses
restricted to the endometrioid histological subtype, the FTO
rs9939609 AA versus TT genotype was slightly strengthened
(OR=1.26; 95% CI: 1.04–1.52; p=0.02) (Table 2), but again
completely attenuated after adjusting for BMI (Table 3). No
associations of the MC4R polymorphism with endometrial cancer
risk were found in any of the models (Figure 2, Tables 2, 3, S2,
and S3).
Discussion
In this pooled analysis of non-Hispanic white women from the
United States, Poland, Canada and Australia, we found that
carriers of the FTO rs9939609 AA genotype were at increased risk
of endometrial carcinoma. This genetic association appears to be
mediated through a relation of rs9939609 to a woman’s weight, as
no independent effect of this SNP was observed after accounting
for BMI.
Experimental evidence suggests that obesity associated SNPs in
intron 1 of the FTO gene are associated with altered gene
expression [23]. Using primer extension analysis, Berulava et al.
[23] determined the ratio of allelic FTO transcript levels in
FTO and MC4R Polymorphisms and Endometrial Cancer
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and fibroblasts of individuals heterozygous for rs9939609. The
FTO transcripts containing the A (‘risk’) allele were more
abundant than those with T allele (mean 1.38; 95% CI: 1.31–
1.44).
The FTO rs9939609 SNP is related to body weight through an
influence on energy intake and satiety [18,24–29]. The rs9939609 A
allele was associated with increased energy intake in adults [25] and
children [24,26–28,30] inseveral epidemiologicalstudies.Den Hoed
et al. [29] reported that women with TA and AA rs9939609
Table 1. Association of FTO rs9939609 and MC4R rs17782313 SNPs with BMI (kg/m
2) in control women.
Genotype All
Lean women (BMI
,25 kg/m
2) Overweight women (BM I$25 kg/m
2)
N( % ) N( % ) N( % )
a OR (95% CI)
a P
FTO rs9939609 4291 2278 2013
TT 1536 (36) 861 (38) 675 (33) 1.00 (reference)
TA 2032 (47) 1069 (47) 963 (48) 1.11 (0.97–1.27) 0.12
AA 723 (17) 348 (15) 375 (19) 1.37 (1.14–1.64) 0.003
Per allele 1.16 (1.06–1.27) 0.001
MC4R rs17782313 3900 2128 1772
TT 2231 (57) 1266 (59) 965 (54) 1.00 (reference)
TC 1390 (36) 720 (34) 670 (38) 1.22 (1.06–1.39) 0.005
CC 279 (7) 142 (7) 137 (8) 1.26 (0.98–1.62) 0.08
Per allele 1.16 (1.05–1.29) 0.004
aOdds ratios (OR), 95% confidence intervals (CI), and pair-wise p-values (1 d.f.) adjusted for age and study.
Note: statistically significant associations (P,0.05) are presented in bold font.
doi:10.1371/journal.pone.0016756.t001
Table 2. Association of the FTO rs9939609 and MC4R rs17782313 with endometrial carcinoma risk.
Genotypes Cases N (%) Controls N (%)
a OR (95% CI)
a P
All women
FTO rs9939609 3561 5167
TT 1236 (35) 1856 (36) 1.00 (reference)
TA 1662 (47) 2463 (48) 0.99 (0.91–1.10) 0.99
AA 663 (18) 848 (16) 1.17 (1.03–1.32) 0.01
Per allele 1.07 (1.01–1.14) 0.04
MC4R rs17782313 3120 4775
TT 1814 (58) 2751 (58) 1.00 (reference)
TC 1094 (35) 1693 (35) 0.98 (0.89–1.08) 0.71
CC 212 (7) 331 (7) 0.97 (0.81–1.18) 0.78
Per allele 0.98 (0.91–1.06) 0.68
Cases with endometrioid carcinoma and controls from studies with available histology data
FTO rs9939609 1403 2778
TT 490 (35) 1025 (37) 1.00 (reference)
TA 648 (46) 1298 (47) 1.04 (0.90–1.21) 0.58
AA 265 (19) 455 (16) 1.26 (1.04–1.52) 0.02
Per allele 1.11 (1.01–1.22) 0.03
MC4R rs17782313 1368 2768
TT 799 (58) 1613 (58) 1.00 (reference)
TC 488 (35) 974 (35) 1.01 (0.87–1.16) 0.96
CC 91 (7) 181 (7) 0.99 (0.76–1.32) 0.99
Per allele 1.01 (0.90–1.12) 0.98
aORs, 95% CIs, and pair-wise p-values (1 d.f.) from the logistic regression models adjusted for age and study.
doi:10.1371/journal.pone.0016756.t002
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PLoS ONE | www.plosone.org 3 February 2011 | Volume 6 | Issue 2 | e16756Figure 1. Association of the FTO rs9939609 with endometrial carcinoma risk in non-Hispanic white women. Forest plot of the ORs and
95% CIs comparing endometrial carcinoma risk for the FTO rs9939609 rare allele homozygotes (AA genotype) versus common allele homozygotes (TT
genotype) for nine studies included in the pooled analysis. The pooled
a OR for all studies was 1.17 [95% CI: 1.03–1.34; p (1 d.f.) =0.01.] P for
heterogeneity of effects by study=0.87. The pooled
b OR for studies including incident cases only (excluding TORONTO study) was 1.18 [95% CI: 1.03–
1.35; p (1 d.f.) =0.02]. P for heterogeneity of effects between studies with incident cases vs. prevalent cases (TORONTO) =0.78. Pooling was
performed by combining all data using study as fixed and random effects (results were the same).
doi:10.1371/journal.pone.0016756.g001
Table 3. Association of the FTO rs9939609 and MC4R rs17782313 with endometrial carcinoma risk among women with BMI data
available.
Cases N (%) Controls N (%) Before adjusting for BMI After adjusting for BMI
a OR (95% CI)
a P
b OR (95% CI)
b P
All women
FTO rs9939609 3061 4291
TT 1063 (35) 1536 (36) 1.00 (reference) 1.00 (reference)
TA 1415 (46) 2032 (47) 0.98 (0.88–1.09) 0.72 0.93 (0.84–1.04) 0.23
AA 583 (19) 723 (17) 1.17 (1.02–1.34) 0.03 1.04 (0.90–1.21) 0.57
Per allele 1.07 (0.99–1.14) 0.07 1.01 (0.94–1.08) 0.84
MC4R rs17782313 2619 3900
TT 1517 (58) 2231 (57) 1.00 (reference) 1.00 (reference)
TC 915 (35) 1390 (36) 0.98 (0.87–1.09) 0.65 0.90 (0.81–1.01) 0.08
CC 187 (7) 279 (7) 1.00 (0.82–1.23) 0.99 0.93 (0.75–1.14) 0.47
Per allele 0.99 (0.91–1.07) 0.78 0.94 (0.86–1.02) 0.12
Cases with endometrioid carcinoma and controls from studies with available histology data
FTO rs9939609 1378 2753
TT 481 (35) 1010 (37) 1.00 (reference) 1.00 (reference)
TA 637 (46) 1289 (47) 1.03 (0.89–1.20) 0.66 1.01 (0.86–1.17) 0.98
AA 260 (19) 454 (16) 1.24 (1.02–1.50) 0.03 1.09 (0.89–1.34) 0.40
Per allele 1.10 (0.99–1.21) 0.05 1.04 (0.94–1.15) 0.47
MC4R rs17782313
TT 1354 2743 1.00 (reference) 1.00 (reference)
TC 785 (58) 1598 (58) 1.01 (0.87–1.16) 0.98 0.91 (0.78–1.06) 0.23
CC 479 (35) 966 (35) 1.01 (0.77–1.33) 0.93 0.93 (0.69–1.25) 0.62
Per allele 90 (7) 179 (7) 1.01 (0.90–1.12) 0.94 0.94 (0.84–1.05) 0.28
aORs, 95% CIs, and pair-wise p-values (1 d.f.) from the logistic regression models adjusted for age and study.
bORs, 95% CIs, and pair-wise p-values (1 d.f.) from the logistic regression models adjusted for age and study, and BMI (continuous variable).
doi:10.1371/journal.pone.0016756.t003
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and satietycompared toTTcarriers.Wardleet al.[24]observedthat
children with two copies of the lower-risk FTO alleles ate less than
those with one or two higher-risk alleles and concluded that the T
allele is protective against overeating by promoting responsiveness to
internal signals of satiety. In addition, two studies reported an
association of the rs9939609 A allele with decreased lipolysis [31,32].
The lack of an independent effect of the MC4R rs17782313
SNP was unexpected and needs further investigation. Although
the power of our MC4R analysis was modest, odds ratios were
close to one, providing no suggestion of an association of this SNP
with endometrial cancer risk among non-Hispanic white women.
Further study of additional genetic correlates of body weight will
assist in clarifying whether the FTO relation to endometrial cancer
risk is unique among ‘obesity-associated’ genes.
A strength of this pooled analysis was the large sample size
available within the E2C2. A large number of genetic variants and
quantitative trait loci that potentially predispose to obesity have
been reported, but only a few have been convincingly confirmed in
multiple independent large scale investigations [33] and FTO
remains the strongest genetic determinant of common obesity
characterized to date. A limitation of this analysis was that
histology was available for only 62% of women. Furthermore, we
did not have detailed information on menopausal hormone use,
weight at different periods in life, body fat distribution, or other
factors that may influence endometrial cancer risk [3]. However,
no association of FTO genotype with menopausal status or
menopausal hormone use was observed in the subset of women
for whom this information was available. Finally, the use of self-
reported height and weight might have resulted in nondifferential
misclassification and thus underestimation of the true effects.
Although important gaps exist in our understanding of the
molecular pathways leading to increased weight and obesity, our
data provide novel evidence that the FTO rs9939609 AA genotype
is associated with endometrial cancer risk among non-Hispanic
white women. As more common genetic variants associated with
overweight and obesity are identified, these might help to identify
the pathways that influence endometrial carcinogenesis.
Methods
Ethics statement
All participating studies were approved by the review boards
and ethics committees of their parent institutions and participating
hospitals, including Queensland Institute of Medical Research,
Brisbane, Australia, for the Australian National Endometrial
Cancer Study (ANECS); the Institutional Review Board (IRB) at
Memorial Sloan-Kettering Cancer Center, NJ, USA, for the
Estrogen, Diet, Genetics, and Endometrial Cancer (EDGE) study;
the IRB of the Fred Hutchinson Cancer Research Center, WA,
USA, for the Fred Hutchinson Cancer Research Center Case-
Control Study (FHCRC); the IRB of the University of Hawaii, HI,
USA, for the Hawaii Endometrial Cancer Study (HAW); the IRBs
of the Universities of Hawaii and Southern California, for the
Multiethnic Cohort Study (MEC); the Committee on Use of
Human Subjects of the Brigham and Women’s Hospital, MA,
USA for the Nurses’ Health Study (NHS); the National Cancer
Institute Central IRB, Bethesda, MD, USA, the Ethical Commit-
tee of The Maria Sklodowska-Curie Memorial Cancer Center and
Institute of Oncology (Warsaw, Poland), and the Bioethical
Committee of the Nofer Institute of Occupational Medicine
(Lodz, Poland) for the Polish Endometrial Cancer Study (PECS);
the Research Ethics Board of the Women’s College Research
Institute, Toronto, ON, Canada, for the Toronto Case-Control
Endometrial Cancer Study; the Committee on Studies Involving
Human Subjects of the University of Pennsylvania, PA, USA, for
the Women’s Insights and Shared Experiences Study (WISE).
Written informed consent was obtained from all participants.
Study Design and Population
Based on Epidemiology of Endometrial Cancer Consortium
(E2C2) procedures, we submitted a formal proposal describing our
hypothesis and methods to the steering committee and to all
consortium members. Genotyping of the proposed SNPs was
performed in the individual laboratories of investigators expressing
an interest in collaboration, following a similar protocol. All data
were combined in the E2C2 coordinating center. Nine studies
Figure 2. Association of the MC4R rs17782313 with endometrial carcinoma risk in non-Hispanic white women. Forest plot of the ORs
and 95% CIs comparing endometrial carcinoma risk for the MC4R rs17782313 rare allele homozygotes (CC genotype) versus common allele
homozygotes (TT genotype) for eight studies included in the pooled analysis. The pooled
a OR for all studies combined was 0.97 [95% CI: 0.81–1.18; p
(1 d.f.) =0.78]. P for heterogeneity of effects by study=0.49. The pooled
b OR for studies including incident cases only (excluding TORONTO study)
was 0.99 [95% CI: 0.81–1.22; p (1 d.f.) =0.94]. P for heterogeneity of effects between studies with incident cases vs. prevalent cases (TORONTO)
=0.68. Pooling was performed by combining all data using study as fixed and random effects (results were the same).
doi:10.1371/journal.pone.0016756.g002
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3601 women with primary incident endometrial carcinoma and
5275 women who were free of endometrial cancer and did not
have history of hysterectomy. Six studies were population-based
case-control studies, two studies were case-control studies nested
within a cohort, and one study was hospital-based. All studies
except the TORONTO study included incident endometrial
cancer cases exclusively. Epidemiological data were collected using
structured questionnaires. All data were combined in the E2C2
coordinating center. Age at diagnosis for cases or age at interview
for controls was available for all study participants. FTO
rs9939609 genotype data were available for 8728 women (3561
cases and 5167 controls) and MC4R rs17782313 genotype data
were available for 7895 women (3120 cases and 4775 controls).
Self-reported BMI data were available for 7459 (84%) of women;
data were missing for women from the Toronto study (n=1313;
14.5%) and for 1.5% of women from other studies. Histology data
were available for 2243 (62%) cases. Data on menopausal status
were available for 907 cases and 885 controls (20%) and use of any
menopausal hormones were available for 3050 cases and 3803
controls (77% of women).
Genotyping
Genotyping was performed in the individual laboratories using 59
nuclease TaqMan allelic discrimination assay (TaqMan, Applied
Biosystems) following the same protocol. We used the following
criteria to measure the acceptability of the genotyping results: (1)
inclusion of $3% sample duplicates, (2) concordance rate for
duplicatesamples$99%,(3)overallcallratebystudy$95%and(4)
intermixing of casesand controls on each plate. Allstudies met these
criteria. Genotyping quality was also assessed using tests for Hardy-
Weinberg equilibrium (HWE). The genotype distribution for both
SNPs among controls was consistent with HWE in all but one study
(WISE, p=0.01) for rs9939609 and one study (NHS, p=0.02) for
rs17782313. Exclusion ofthese studies didnotappreciably affectthe
reported results. MC4R rs17782313 genotype data were not
available for the PEC study (417 cases and 407 controls).
Statistical analysis
All analyses were completed in the SAS statistical software
package version 9.2 (SAS Institute Inc., Cary, NC). Fisher’s
goodness-of-fit test was used to assess whether allele frequency
distributions among controls were consistent with HWE. Uncon-
ditional multiple logistic regression models were used to calculate
odds ratios (ORs) and 95% confidence intervals (CIs) for the
association of genotype with endometrial cancer risk and BMI,
calculated as the ratio of weight in kilograms divided by the square
of height in meters. BMI was used as continuous variable, as well
as categorical with two levels: lean women (BMI ,25 kg/m
2) and
overweight women (BMI $25 kg/m
2). The genotype for each
SNP was treated as a non-ordered categorical variable to test for
heterogeneity and as an ordered categorical variable (with three
levels: 0, 1, 2; one assigned to each genotype) to test for an allele-
dose effect. Homozygous carriers of the common FTO rs9939609
and MC4R rs17782313 T alleles were used as the reference group
for these models. Heterogeneity of effects by study was examined
using two different methods. First, we included study site as a fixed
effect covariate and evaluated heterogeneity of the association of
genotypes with risk by study, using a Wald test of the genotype-
study interaction term. Second, we included study site as a random
effect using SAS GLIMMIX procedure (the results were the same).
To evaluate potential confounders, the distributions of genotypes
among controls were examined by factors associated with ovarian
cancer risk (age, menopausal status, and use of menopausal
hormones) (Table S5). Age (continuous variable) was included in
all models to account for residual confounding by imperfect
matching. A Wald test was used to compare the associations of
genotypes with endometrial cancer risk by study and BMI strata.
Power calculations were performed using QUANTO software
(http:hydra.usc.edu/gxe) and were based on population incidence
rates of endometrial cancer of 24.4 per 100,000 women per year.
These rates are based on cases diagnosed in 2001–2005 from 17
Surveillance Epidemiology and End Results (SEER) geographic
areas [1]. Calculated minimal detectable ORs (MDOR) are
presented in Table S6.
Table 4. Description of the studies included in the pooled analysis of FTO rs9939609 and MC4R rs17782313 and endometrial
carcinoma risk.
Study Name Location Study Design Cases (N) Mean age (SD), yrs Controls (N) Mean age (SD), yrs
ANECS (Australian National
Endometrial Cancer Study)
Australia Population-based
case-control
877 62.0 (9.3) 860 56.3 (12.0)
EDGE (Estrogen, Diet, Genetics, and
Endometrial Cancer)
New Jersey, USA Population-based
case-control
258 61.8 (9.3) 233 65.2 (9.9)
FHCRC (Fred Hutchinson Cancer
Research Center Case-Control Study)
Washington, USA Population-based
case-control
719 59.7 (6.1) 730 59.2 (6.1)
HAW (Hawaii Endometrial Cancer
Study)
Hawaii, USA Population-based
case-control
42 64.5 (10.3) 146 56.6 (11.2)
MEC (Multiethnic Cohort Study) California and Hawaii, USA Nested case-control 73 64.9 (8.2) 337 61.7 (8.8)
NHS (Nurses’ Health Study) 11 US States Nested case-control 484 62.8 (8.4) 1195 62.4 (8.2)
PECS (Polish Endometrial Cancer
Study)
Lodz and Warsaw, Poland Population-based
case-control
417 60.8 (8.4) 407 60.9 (8.9)
TORONTO (Toronto Case-Control
Endometrial Cancer Study)
Canada Hospital-based
case-control
454 60.7 (12.1) 859 56.2 (10.2)
WISE (Women’s Insights and Shared
Experiences)
Pennsylvania, USA Population based
case-control
277 63.0 (8.1) 508 62.0 (8.1)
POOLED 3601 61.5 (8.9) 5275 59.7 (9.7)
doi:10.1371/journal.pone.0016756.t004
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